6 research outputs found
Social Transmission and the Spread of Modern Contraception in Rural Ethiopia
Socio-economic development has proven to be insufficient to explain the time and pace of the human demographic transition. Shifts to low fertility norms have thus been thought to result from social diffusion, yet to date, micro-level studies are limited and are often unable to disentangle the effect of social transmission from that of extrinsic factors. We used data which included the first ever use of modern contraception among a population of over 900 women in four villages in rural Ethiopia, where contraceptive prevalence is still low (<20%). We investigated whether the time of adoption of modern contraception is predicted by (i) the proportion of ever-users/non ever-users within both women and their husbands' friendships networks and (ii) the geographic distance to contraceptive ever-users. Using a model comparison approach, we found that individual socio-demographic characteristics (e.g. parity, education) and a religious norm are the most likely explanatory factors of temporal and spatial patterns of contraceptive uptake, while the role of person-to-person contact through either friendship or spatial networks remains marginal. Our study has broad implications for understanding the processes that initiate transitions to low fertility and the uptake of birth control technologies in the developing world
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Background There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes.Methods We evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation.Results Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials. Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges.Conclusions Understanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective.Trial registration FOCUS4: ISRCTN Registry, ISRCTN90061546 . Registered on 16 October 2013.Stampede ISRCTN Registry, ISRCTN78818544 . Registered on 2 February 2004
This is a Platform Alteration: A Trial Management Perspective on the Operational Aspects of Adaptive and Platform and Umbrella Protocols
Background
There is limited research and literature on the trial management challenges encountered in running
adaptive platform trials. This trial design allows both (i) seamless addition of new research
comparisons when compelling clinical and scientific research questions emerge, and (ii) early
stopping of accrual to individual comparisons that do not show sufficient activity without affecting
other active comparisons. Adaptive platform design trials also offer many potential benefits over
traditional trials, from faster time to accrual to contemporaneously recruiting multiple research
comparisons, added flexibility to focus on more promising research comparisons via pre-planned
interim analyses and potentially shorter time to primary results. We share here our experiences
from a trial management perspective, highlighting the challenges and successes.
Methods
We evaluated the operational aspects of making changes to these adaptive platform trials and
identified both common and trial-specific challenges. The operational steps and challenges linked to
both the addition of new research comparisons and stopping recruitment following pre-planned
interim analysis were considered in our evaluation.
Results
Specific operational challenges in these adaptive platform protocols, additional to those in
traditional two-arm trials, were identified. Key lessons are presented describing some of the
solutions and considerations over conducting these trials.
Careful consideration on the practicality of the protocol structure (modular versus single protocol),
the longevity and continuity of trial oversight committees and having clear clinical and scientific
criteria for the addition of new research comparisons were identified as some of the most common
challenges.
Page 6 of 33
Conclusions
Understanding the operational complexities associated with running adaptive platform protocols is
paramount for their conduct, adaptive platform trials offer an efficient model to run randomised
controlled trials and we are continuing to work to reduce further the effort required from an
operational perspective.
Trial Registration FOCUS4 (ISRCTN90061546); STAMPEDE (ISRCTN78818544